Beretta P, Franchi M, Zanaboni F, Confalonieri S, Salvatore S
Clinica Ostetrico-Ginecologica, Ospedale di Circolo e Fondazione Macchi, Varese.
Minerva Ginecol. 1993 Oct;45(10):467-71.
In the Department of Obstetric and Gynecology, Faculty of Medicine-Varese, between March 1991 and June 1992, 74 consecutive patients undergoing elective oncologic surgery were evaluated in order to rationalize the use of antibiotics to decrease the costs of infectious complications. We divided the patients into two groups: a high infection risk group (in which every patient was submitted to antibiotic prophylaxis) and a low infection risk group (in which we didn't use any antibiotic prophylaxis). Our findings indicate that selection criteria for HIR patients are probably correct and in this group AP is necessary. In the LIR group, 45.5% of patients was not submitted to any antibiotic therapy. It's necessary to test the real efficacy of an AP in LIR patients in whom we had not a important incidence of infectious complications. In the LIR group AP should not exceed Lit. 23,251 per patient to be cost-effective.
1991年3月至1992年6月期间，在瓦雷泽医学院妇产科，对74例连续接受择期肿瘤手术的患者进行了评估，以合理使用抗生素，降低感染并发症的成本。我们将患者分为两组：高感染风险组（每组患者均接受抗生素预防）和低感染风险组（未使用任何抗生素预防）。我们的研究结果表明，高感染风险患者的选择标准可能是正确的，在该组中抗生素预防是必要的。在低感染风险组中，45.5%的患者未接受任何抗生素治疗。有必要测试抗生素预防在低感染风险患者中的实际疗效，这些患者感染并发症的发生率并不高。在低感染风险组中，为了具有成本效益，每位患者的抗生素预防费用不应超过23,251里拉。
